We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Discovery Stage COVID-19 Antigen Presentation Therapeutic Biologics Mix to Treat COVID-19 Virus Infection (ApTpBioMix)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03348670
Recruitment Status : Active, not recruiting
First Posted : November 21, 2017
Last Update Posted : January 14, 2022
Sponsor:
Information provided by (Responsible Party):
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, Medicine Invention Design, Inc

Brief Summary:

Conducting an initial, small, controlled clinical trial to assess for COVID-19 Antigen Presentation Therapeutic Biologics Mix activity that suggests the potential for clinical benefit of COVID-19 patients.

  1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains.
  2. Activate human COVID-19 Antigen Presentation Reaction.
  3. The human antigen presenting cells (APCs) can treat the COVID-19 virus antigens into small peptide fragments, and then kill COVID-19 virus directly.

Condition or disease Intervention/treatment Phase
Covid19 Biological: CoronaVac® plus TICE® BCG Mix for Intradermal Injection Early Phase 1

Detailed Description:
  • Conducting an initial, small, controlled clinical trial to assess for COVID-19 Antigen Presentation Therapeutic Biologics Mix activity that suggests the potential for clinical benefit of COVID-19 patients
  • 20 Lower Than Mild COVID-19 Patients
  • Positive testing COVID-19 by standard RT-PCR assay
  • COVID-19 infection without symptoms
  • Symptoms of mild illness with COVID-19 that could include fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, and loss of taste or smell, without shortness of breath or dyspnea
  • No clinical signs indicative of Moderate, Severe, or Critical Severity
  • PPD negative participant is 10 TU skin test reading < 5 mm induration at 48 hours
  • Our trial duration will be 4-week duration.
  • CoronaVac® Organism 1.0 mL plus TICE® BCG Organism 50 MG Mix
  • Intradermic Injection, ID
  • Our trial duration will be 4-week duration
  • Negative testing COVID-19 by standard RT-PCR assay after injection 2 weeks

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
  • Single Usage
  • Single Dosage
Masking: None (Open Label)
Masking Description: Open Label
Primary Purpose: Treatment
Official Title: Conducting an Initial, Small, Controlled Clinical Trial to Assess for COVID-19 Antigen Presentation Therapeutic Biologics Mix Activity That Suggests the Potential for Clinical Benefits of COVID-19 Patients.
Actual Study Start Date : October 20, 2021
Estimated Primary Completion Date : March 28, 2022
Estimated Study Completion Date : March 28, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Assess for COVID-19 Antigen Presentation Therapeutic Biologics Mix activity
  • CoronaVac® Organism 1.0 mL
  • TICE® BCG Organism 50 MG
Biological: CoronaVac® plus TICE® BCG Mix for Intradermal Injection
  • Intradermic Injection, ID
  • CoronaVac® Organism 1.0 mL plus TICE® BCG Organism 50 MG Mix
Other Name: CoronaVac® Organism plus TICE® BCG Organism Mix




Primary Outcome Measures :
  1. Negative testing COVID-19 by standard RT-PCR assay [ Time Frame: Duration at least 28 days ]
    Negative testing COVID-19 by standard RT-PCR assay after injection 2 weeks



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   24 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • Conducting an initial, small, controlled clinical trial to assess for COVID-19 Antigen Presentation Therapeutic Biologics Mix that suggests the potential for clinical benefit of COVID-19 patients.
  • 20 Lower Than Mild COVID-19 Patients

Inclusion Criteria:

  • Lower Than Mild COVID-19 Patients
  • Positive testing COVID-19 by standard RT-PCR assay
  • COVID-19 infection without symptoms
  • Symptoms of mild illness with COVID-19 that could include fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, and loss of taste or smell, without shortness of breath or dyspnea
  • No clinical signs indicative of Moderate, Severe, or Critical Severity
  • PPD negative participant is 10 TU skin test reading < 5 mm induration at 48 hours.

Exclusion Criteria:

  • PPD positive participant is 10 TU skin test reading > 5 mm induration at 48 hours
  • Symptoms of moderate illness with COVID-19, which could include any symptom of mild illness or shortness of breath with exertion
  • Clinical signs suggestive of moderate illness with COVID-19
  • Symptoms suggestive of severe systemic illness with COVID-19, which could include any symptom of moderate illness or shortness of breath at rest, or respiratory distress
  • Clinical signs indicative of severe systemic illness with COVID-19
  • Evidence of critical illness
  • Respiratory failure
  • Shock
  • Multi-organ dysfunction / failure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03348670


Locations
Layout table for location information
United States, Maryland
MIDI Clinical Trial Sites -c/o- Dr. Han Xu - Sponsor / Investigators / Physicians / Laboratories Operation Site
Rockville, Maryland, United States, 20853
Sponsors and Collaborators
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Investigators
Layout table for investigator information
Study Chair: HAN XU, MD/PhD/FAPCR IRB00009424
Study Director: HAN XU, MD/PhD/FAPCR IORG0007849
Principal Investigator: HAN XU, MD/PhD/FAPCR IORG0007849-FWA00015357
  Study Documents (Full-Text)

Documents provided by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, Medicine Invention Design, Inc:
Study Protocol  [PDF] January 11, 2022
Informed Consent Form  [PDF] January 11, 2022

Additional Information:
Publications:

Layout table for additonal information
Responsible Party: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, M.D., Ph.D., FAPCR, Sponsor-Investigator, IORG Director, Medical Monitor, Safety Officer, IRB Chair, Medicine Invention Design, Inc
ClinicalTrials.gov Identifier: NCT03348670    
Other Study ID Numbers: IND158083
FWA00015357 ( Registry Identifier: DHHS-OHRP-FWA )
IRB00009424 ( Registry Identifier: DHHS-OHRP-IRB )
IORG0007849 ( Registry Identifier: DHHS-OHRP-IORG )
IND158083 ( Registry Identifier: FDA-IND )
NDA216636 ( Registry Identifier: FDA-NDA )
BLA761273 ( Registry Identifier: FDA-BLA )
First Posted: November 21, 2017    Key Record Dates
Last Update Posted: January 14, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, Medicine Invention Design, Inc:
Escape Mutation
ADE
Antigen Presentation
APC
Trained Immunity
Spike
innate immune memory
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
BCG Vaccine
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs